Prostate Cancer Group Archives

Presented at ASCO GU 2025, results of the phase 3 TALAPRO-2 trial support a new standard-of-care for metastatic castration-resistant prostate cancer

Results of the multi-center, international phase 3 TALAPRO-2 trial show that the combination of PARP inhibitor talazoparib plus anti-androgen enzalutamide…

RAD51 biomarker could complement next-generation sequencing in personalizing prostate cancer treatment

Published in Cell Reports Medicine*, results of a VHIO-led study support the feasibility of using RAD51 testing to complement next-generation…